JP6549126B2 - 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット - Google Patents

生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット Download PDF

Info

Publication number
JP6549126B2
JP6549126B2 JP2016539674A JP2016539674A JP6549126B2 JP 6549126 B2 JP6549126 B2 JP 6549126B2 JP 2016539674 A JP2016539674 A JP 2016539674A JP 2016539674 A JP2016539674 A JP 2016539674A JP 6549126 B2 JP6549126 B2 JP 6549126B2
Authority
JP
Japan
Prior art keywords
mvp
solution
protein
binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016539674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529908A5 (https=
JP2016529908A (ja
Inventor
デイビッド セトリン,
デイビッド セトリン,
アルン ダール,
アルン ダール,
Original Assignee
モックヴィー ソリューションズ, インコーポレイテッド
モックヴィー ソリューションズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モックヴィー ソリューションズ, インコーポレイテッド, モックヴィー ソリューションズ, インコーポレイテッド filed Critical モックヴィー ソリューションズ, インコーポレイテッド
Publication of JP2016529908A publication Critical patent/JP2016529908A/ja
Publication of JP2016529908A5 publication Critical patent/JP2016529908A5/ja
Application granted granted Critical
Publication of JP6549126B2 publication Critical patent/JP6549126B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/23Parvoviridae, e.g. feline panleukopenia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/015Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016539674A 2013-09-10 2014-09-09 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット Active JP6549126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875729P 2013-09-10 2013-09-10
US61/875,729 2013-09-10
PCT/IB2014/064352 WO2015036917A2 (en) 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118216A Division JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Publications (3)

Publication Number Publication Date
JP2016529908A JP2016529908A (ja) 2016-09-29
JP2016529908A5 JP2016529908A5 (https=) 2017-11-16
JP6549126B2 true JP6549126B2 (ja) 2019-07-31

Family

ID=52625972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016539674A Active JP6549126B2 (ja) 2013-09-10 2014-09-09 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット
JP2019118216A Withdrawn JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019118216A Withdrawn JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Country Status (7)

Country Link
US (4) US9632087B2 (https=)
EP (1) EP3044339B1 (https=)
JP (2) JP6549126B2 (https=)
CN (1) CN105899684B (https=)
AU (3) AU2014320015B2 (https=)
DK (1) DK3044339T3 (https=)
WO (1) WO2015036917A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9632087B2 (en) 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles
EP3882627B1 (en) * 2018-11-14 2024-07-10 Nissan Chemical Corporation Container and method for storing, pretreating, and analyzing biomaterial
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
CN118465260B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 测定逆转录病毒包膜蛋白elisa方法的建立及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966987A (en) * 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
US5173399A (en) * 1988-06-10 1992-12-22 Abbott Laboratories Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests
IL92298A (en) * 1988-11-14 2001-04-30 Us Secretary U S Dept Of Comme Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5814442A (en) * 1994-06-10 1998-09-29 Georgetown University Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
EP1268841A4 (en) 2000-03-27 2005-03-09 Smithkline Beecham Corp DETECTING VIABLE AGENTS
EP1170367A1 (en) * 2000-06-27 2002-01-09 Bayer Ag BVDV virus-like particles
US20040002058A1 (en) * 2001-06-21 2004-01-01 Uab Research Foundation Chimeric capsid proteins and uses thereof
US7041444B2 (en) * 2003-01-14 2006-05-09 Washington University Murine calicivirus
US20050196381A1 (en) * 2003-09-09 2005-09-08 Xiaobin Lu Lentivirus vector-based approaches for generating an immune response to HIV in humans
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007146197A1 (en) * 2006-06-09 2007-12-21 Xing-Xiang Li Methods and reagents for virus isolation and detection
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
EP2198020B1 (en) * 2007-09-14 2016-04-13 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0803068D0 (en) * 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
MX2011004201A (es) * 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
BR112012025364A2 (pt) * 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
US9644187B2 (en) * 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US9632087B2 (en) * 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles

Also Published As

Publication number Publication date
WO2015036917A2 (en) 2015-03-19
JP2016529908A (ja) 2016-09-29
AU2014320015B2 (en) 2020-10-29
AU2021200484A1 (en) 2021-02-25
AU2023229501B2 (en) 2025-04-03
US20150072339A1 (en) 2015-03-12
US9632087B2 (en) 2017-04-25
AU2023229501A1 (en) 2023-09-28
EP3044339B1 (en) 2019-05-22
EP3044339A4 (en) 2017-04-26
WO2015036917A3 (en) 2015-12-03
CN105899684A (zh) 2016-08-24
CN105899684B (zh) 2021-06-11
US12553894B2 (en) 2026-02-17
AU2021200484B2 (en) 2023-06-29
AU2014320015A1 (en) 2016-03-31
US10309963B2 (en) 2019-06-04
US11754565B2 (en) 2023-09-12
JP2019195333A (ja) 2019-11-14
US20240085419A1 (en) 2024-03-14
US20170192001A1 (en) 2017-07-06
US20190353656A1 (en) 2019-11-21
EP3044339A2 (en) 2016-07-20
DK3044339T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
US12553894B2 (en) Methods and kits for quantifying the removal of mock virus particles from a purified solution
Tustian et al. Assessment of quality attributes for adeno‐associated viral vectors
TWI735433B (zh) 偵測生物污染物之組成物及方法
Boix-Besora et al. Optimization, production, purification and characterization of HIV-1 GAG-based virus-like particles functionalized with SARS-CoV-2
JP2016523812A (ja) タンパク質のピログルタミン酸形成を増加させるための方法
JP2537850B2 (ja) レトロウイルスを含まぬ免疫グロブリンの製法
WO2022262206A1 (zh) Gmp级逆转录病毒载体的纯化方法与应用
Janc et al. In-depth comparison of adeno-associated virus containing fractions after CsCl ultracentrifugation gradient separation
JP2016529908A5 (https=)
CN105861530B (zh) 承载GAD65 p271-284肽段的I-Ag7果蝇细胞高表达基因序列和构建的Tetramer
Xiao et al. Enhanced expression of GCRV VP6 in CIK cells by relative sequence optimization
CN119039427B (zh) 一株绵羊抗蓝舌病毒的重组单个b细胞抗体
CN120737193B (zh) 一种抗Oya病毒核衣壳蛋白的单克隆抗体或其抗原结合片段及其应用
CN119798382B (zh) 一种人乳头瘤病毒16型突变型e2蛋白及其应用
WO2023231149A1 (en) Recombinant orthohepevirus genotype c1 orf2 protein and preparation method therefor and use thereof
EP3250696B1 (en) Stock solution of retrovirus like particles with method
Eilts Picking The Best Virus Sample Prep Method In Process Development
CN118853595A (zh) 脱脚病病毒和小鼠腺病毒假病毒制备方法及其在分子检测中的应用
CN118638825A (zh) 一种多重鼠源rna假病毒、制备方法及其应用
CN119842809A (zh) 一种hpv中和抗体假病毒及其制备方法和应用
Peetermans Quality Control of Vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190626

R150 Certificate of patent or registration of utility model

Ref document number: 6549126

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250